[Initial clinical experiences with a transvenous-subcutaneous defibrillation system]

Abstract

In 19 patients with an indication for an implantable defibrillator, it was tried to avoid thoracotomy by using two electrodes positioned via the subclavian vein in the right ventricle (for pacing, sensing, and defibrillation) and the superior vena cava or coronary sinus (for defibrillation), and one electrode positioned subcutaneously near the ventricular apex (for defibrillation). In 17 patients (89%) the transvenous-subcutaneous leads were implanted, whereas in the remaining two patients an epi-/pericardial lead system was subsequently used due to an insufficient defibrillation threshold. Perioperatively, no major complications were observed and patients were rapidly mobilized. Within a follow-up period of 7 +/- 4 months, no malfunction of the lead system became evident. Sixty-eight episodes of spontaneous ventricular tachyarrhythmias occurred, all of which were successfully terminated. In one patient an infection of the lead system developed after 2 months that proved refractory to antibiotics and required surgical removal. Thus, transvenous-subcutaneous placement of leads for implantable defibrillators yielded a sufficient defibrillation threshold in the majority of patients. Long-term efficacy was excellent and no malfunctions were observed. This approach seems to be feasible and advisable in patients with an increased risk for thoracotomy.